top of page
PRESS
Recardio signs letter of intent with Kancera for licensing of cardiometabolic assets
San Francisco, March 7, 2025 - Recardio Inc., a late clinical-stage life science company developing therapies for cardiovascular and...
Mar 7, 20253 min read
Recardio at J.P. Morgan 2025
San Francisco, January 9, 2025 - Recardio Inc., a late-stage clinical-stage life science company focusing on therapies for cardiovascular...
Jan 9, 20251 min read
New International Patent Application
San Francisco, December 4, 2024 - Recardio Inc., a late stage clinical stage life science company developing therapies for cardiovascular...
Dec 4, 20242 min read
bottom of page